Results 21 to 30 of about 28,392 (204)

Metformin and berberine prevent olanzapine-induced weight gain in rats. [PDF]

PLoS ONE, 2014
Olanzapine is a first line medication for the treatment of schizophrenia, but it is also one of the atypical antipsychotics carrying the highest risk of weight gain.
Yueshan Hu, Alan J Young, Erik A Ehli, Dustin Nowotny, Paige S Davies, Elizabeth A Droke, Timothy J Soundy, Gareth E Davies   +7 more
doaj   +1 more source

Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies [version 1; peer review: 2 approved]

F1000Research, 2022
Background: Olanzapine is used to treat schizophrenia and bipolar disorder in women of childbearing age. Continuation of psychotropic medications throughout pregnancy and lactation is often required as cessation could be dangerous for both mother and ...
Mark Habgood, Katarzyna Dziegielewska, Yifan Huang, Shuai Nie, Fiona Qiu, Norman Saunders   +5 more
doaj   +1 more source

Zebrafish shares common metabolic pathways with mammalian olanzapine-induced obesity

Future Journal of Pharmaceutical Sciences, 2020
Background Olanzapine is one of the most prescribed antipsychotic agents in the pharmacotherapy of psychiatric illness; however, it is associated with multiple side effects primarily obesity. Multiple investigations have been made to model the olanzapine-
Pukar Khanal, B. M. Patil, Banappa. S. Unger   +2 more
doaj   +1 more source

Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Olanzapine has been shown to have an additive effect on the three-drug antiemetic therapy consisting of aprepitant, palonosetron, and dexamethasone, in a highly emetogenic cisplatin-containing chemotherapy.
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi   +6 more
doaj   +1 more source

Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies [version 2; peer review: 2 approved]

F1000Research, 2023
Background: Olanzapine is used to treat schizophrenia and bipolar disorder in women of childbearing age. Continuation of psychotropic medications throughout pregnancy and lactation is often required as cessation could be dangerous for both mother and ...
Mark Habgood, Katarzyna Dziegielewska, Yifan Huang, Shuai Nie, Fiona Qiu, Norman Saunders   +5 more
doaj   +1 more source

OLANZAPINE AND HYPERTRIGLYCERIDEMIA

Journal of the American Academy of Child & Adolescent Psychiatry, 2001
Journal of the American Academy of Child & Adolescent Psychiatry 40 (2001) 133-133.
Division of Child and Adolescent Psychiatry, University of Florida, Gainesville ( host institution ), Nguyen, Mathew, Murphy, Tanya   +2 more
openaire   +3 more sources

Automated Dynamic Flow Experimentation for Rapid Kinetic Fitting of Transition Metal Catalysis

Angewandte Chemie, EarlyView.
We have developed an automated dynamic flow experimentation platform to automatically fit and identify the most accurate kinetic model from a generated set of candidates. Three transition metal‐catalyzed transformations were performed using this workflow.
Florian L. Wagner, Klara Silber, Tobias A. Doliner, C. Oliver Kappe   +3 more
wiley   +2 more sources

Macrophage-derived secretome is sufficient to confer olanzapine-mediated insulin resistance in human adipocytes

Comprehensive Psychoneuroendocrinology, 2021
Objective: Olanzapine and Aripiprazole are widely used second-generation antipsychotic drugs. Olanzapine, more than Aripiprazole, leads to considerable metabolic side effects including obesity and diabetes.
Priya Dipta, Assel Sarsenbayeva, Miriam Shmuel, Francesca Forno, Jan W. Eriksson, Maria J. Pereira, Xesús M. Abalo, Martin Wabitsch, Morten Thaysen-Andersen, Boaz Tirosh   +9 more
doaj   +1 more source

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]

Neuropsychiatric Disease and Treatment, 2021
Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904. The authors have advised there is an error in Figure 1C on page 2894.
Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D   +9 more
doaj  

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source